FDA Approves Xadago to Treat Parkinson’s Disease

(March 22, 2017) – U.S. regulators have approved the first new drug in a decade for Parkinson’s disease, The Food and Drug Administration has approved Xadago for use when a patient’s regular medicines aren’t working well. Newron Pharmaceuticals developed Xadago, known chemically as safinamide and its partner in the U.S., US Worldwide Meds, will market Xadago in this country. Read more…